International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationPleural Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma
Introduction
Malignant pleural mesothelioma (MPM) is difficult to treat because of its locally aggressive behavior. Controversy surrounds the optimal treatment of early-stage mesothelioma; however, studies using multimodality therapy have shown promising local control and survival. Because the most common site of treatment failure for MPM is the ipsilateral hemithorax, optimizing local control provides the best chance for long-term survival.
Two types of surgery are performed for mesothelioma: extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). EPP involves en bloc resection of the entire pleura, lung, diaphragm, and ipsilateral half of the pericardium. P/D involves resection of all gross tumor without removing the lung. Neither P/D nor EPP alone offers adequate long-term local control or survival. After EPP, adjuvant hemithoracic radiotherapy (RT) to the chest cavity has been shown to improve local control and survival; however, distant failure remains a problem. A number of studies have investigated whether more advanced RT techniques, such as intensity-modulated RT (IMRT), lead to better local control than standard RT after EPP. However, IMRT can be associated with increased toxicity, including fatal pneumonitis, if radiation exposure to the remaining lung is not carefully restricted 1, 2, 3.
More recently, enthusiasm for EPP has waned, particularly because this surgery is associated with increased morbidity and mortality relative to P/D. A report compiling the data from 663 MPM patients treated surgically suggested that those who underwent EPP had inferior survival compared with patients who underwent P/D (4). Although that analysis was subject to significant retrospective biases, it has had a major influence on the practice of many thoracic surgeons. However, with P/D, local control remains the primary issue and RT is more challenging to administer because of the risk of pneumonitis in the intact lung. Our previous institutional experience with standard pleural RT was not promising (5). The difference in the effectiveness of RT in these situations can be partially explained because complete removal of the ipsilateral lung with EPP allows the delivery of greater radiation doses. However, implementation of an IMRT technique could enable greater doses to be administered even with an intact lung and thus might improve efficacy. The present study reports on our experience using a novel technique to treat the pleura with IMRT.
Section snippets
Methods and Materials
A total of 36 patients with biopsy-proven MPM underwent IMRT to the hemithorax without pneumonectomy at the Memorial Sloan-Kettering Cancer Center between 2005 and 2010. Of these 36 patients, 11 were enrolled in a Memorial Sloan-Kettering Cancer Center institutional review board–approved feasibility protocol. The others were treated after the feasibility of the technique had been established. Their records were reviewed with an institutional review board waiver. Not all patients were candidates
Results
The median radiation dose was 4,680 cGy (range, 4,140–5,040). The incidence of acute treatment-related toxicity is listed in Table 2. The patients were able to complete treatment with medical support and without the need for treatment breaks. No patients required intravenous hydration during treatment. One patient required the placement of a percutaneous endoscopic gastrostomy tube before the initiation of RT because of a poor nutritional status and was able to maintain an adequate nutritional
Discussion
Our results have demonstrated that pleural IMRT for patients with MPM and an intact ipsilateral lung is a feasible treatment option with an acceptable toxicity profile. Historically, our institution has favored EPP, followed by adjuvant hemithorax RT for treatment of MPM. In a Phase II trial, the median survival was 17 months using this treatment paradigm (15). The RT was well tolerated, because removal of the ipsilateral lung during EPP minimized pleural toxicity. The median overall survival
References (19)
- et al.
Intensity-modulated radiation therapy: A novel approach to the management of malignant pleural mesothelioma
Int J Radiat Oncol Biol Phys
(2003) - et al.
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma
Int J Radiat Oncol Biol Phys
(2006) - et al.
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma
Int J Radiat Oncol Biol Phys
(2007) - et al.
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma
Int J Radiat Oncol Biol Phys
(2005) - et al.
Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: A strategy for large-scale implementation for the treatment of carcinoma of the prostate
Int J Radiat Oncol Biol Phys
(1997) - et al.
A comprehensive three-dimensional radiation treatment planning system
Int J Radiat Oncol Biol Phys
(1988) - et al.
Fitting of normal tissue tolerance data to an analytic function
Int J Radiat Oncol Biol Phys
(1991) - et al.
Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations
Int J Radiat Oncol Biol Phys
(1991) - et al.
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma
J Thorac Cardiovasc Surg
(2001)
Cited by (0)
Conflict of interest: none.